The FDA receives raw and cleaned datasets from sponsors, not just summary reports. Their internal teams conduct independent analyses, which can lead to findings or data presentations in the official drug label that differ from or expand upon what's in the published paper.

When asked if they would investigate a safety concern for a specific drug at an external party's request, the FDA expressed reluctance. Such an analysis would raise questions of bias. Instead, they prefer to address these questions by pooling data from multiple drugs with a similar mechanism of action.

Dr. Smith highlights a critical flaw in pharmacology: while a single drug undergoes rigorous FDA testing, there is zero data on the interactive effects when a patient takes two or more drugs concurrently. This 'polypharmacy' creates unpredictable and potentially harmful side effects.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

Contrary to widespread belief, generic drugs are not always identical to brand-name versions. Experts estimate a 13% failure rate, meaning they may lack potency, contain contaminants like arsenic, or have faulty delivery mechanisms, posing significant safety risks.

An FDA analysis of Complete Response Letters (CRLs) since 2020 revealed that 70% of drug approval rejections were due to CMC issues. This data underscores that manufacturing and control strategies are a primary gatekeeper for regulatory approval, not just clinical trial results.

Clinicians should avoid directly comparing the toxicity profiles of new ADCs, as the data often comes from different trial stages. A drug in a Phase 1 expansion cohort may appear more toxic than one with mature Phase 2 randomized data, making definitive safety assessments premature.

MedShadow's reporting reveals the manufacturer on a drug bottle is often a parent company, obscuring a complex supply chain of actual plants in countries like China or India. This lack of transparency makes tracking drug safety and quality nearly impossible for consumers.

Unlike the EU's strict approval process for new chemicals, the U.S. allows companies to self-declare novel compounds as "Generally Recognized as Safe" (GRAS). This has resulted in tens of thousands of chemicals in the U.S. food system that are not permitted in the EU, contributing to the chronic disease crisis.